  STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
Protocol No. RHB -104-04 
 
  
  
  
  
  
SSTTAATTIISSTTIICCAALL  AANNAALLYYSSIISS  PPLLAANN  
 
 
RedHill Biopharma Ltd.  
21 Ha’arba’a St.,  
Tel-Aviv 64739, Israel  
 
An Open Label Study to Assess the Efficacy and Safety of 
Fixed -Dose Combination RHB -104 in  
Subjects with Active Crohn’s Disease Despite 26 Weeks of 
Participat ion in the MAP US  
RHB -104-01 Study  
 
Protocol No. RHB -104-04 
 
 
 
Prepared by  
Shuhong Zhao , PhD  
Principal Research Biostatistician  
 
Syneos  Health  
 
 
 
 
 
This document contains confidential information of RedHill Biopharma Ltd.  Any viewing or 
disclosure of such  information that is not authorized in writing by RedHill Biopharma Ltd.  is 
strictly prohibited.  Such information may be used solely for the purpose of reviewing or 
performing this study.  
  STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
Protocol No. RHB -104-04 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  1   
SSTTAATTIISSTTIICCAALL  AANNAALLYYSSIISS  PPLLAANN  
SSIIGGNNAATTUURREE  PPAAGGEE**  
 
RedHill Biopharma Ltd.  
21 Ha’arba’a St.,  
Tel-Aviv 64739, Israel  
 
An Open Label Study to Assess the Efficacy and Safety of 
Fixed -Dose Combination RHB -104 in  
Subjects with Active Crohn’s Disease Despite 26 Weeks of 
Participation in the MAP US  
RHB -104-01 Study  
 
Protocol No. RHB -104-04 
Final version 1.0 Dated  16 December 2016 
 
 
 
 
M. Scott Harris  MD 
Medical Lead  
RedHill Biopharma Ltd.  Approval Date  
  
Shuhong Zhao, PhD  
Principal Research  Biostatistician  
inVentiv Health Clinical  Approval Date  
  
Jed Henke  
Manager, Biostatistics  
inVentiv Health  Clinical  Approval Date  
  
 
  STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
Protocol No. RHB -104-04 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  2  
 
 
 
STATISTICAL ANALYSIS PLAN  
 
REVISION HISTORY  
 
TThhiiss  iiss  ffiirrsstt  vveerrssiioonn
  STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
Protocol No. RHB -104-04 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  3   
TTAABBLLEE  OOFF  CCOONNTTEENNTTSS  
 
 
LIST OF ABBREVIATIONS AND DEFINITIONS  ................................ ................................ ......................  5 
1. INTRODUCTION ................................ ................................ ................................ .............................  8 
2. STUDY OBJECTIVES AND ENDPOINTS  ................................ ................................ ....................  9 
2.1 Study Objectives  ................................ ................................ ................................ ..............................  9 
2.1.1  Primary Objective  ................................ ................................ ................................ ................  9 
2.1.2  Secondary Objective  ................................ ................................ ................................ ............  9 
2.1.3  Selected Other Secondary Objec tives  ................................ ................................ ..................  9 
2.1.4  Selected Other Objectives  ................................ ................................ ................................ .... 9 
2.1.5  Safety Objective  ................................ ................................ ................................ ................  10 
2.2 Outcomes/Endpoints  ................................ ................................ ................................ ......................  10 
2.2.1  Primary Endpoint/Variable: Remission  ................................ ................................ .............  10 
2.2.2  Key Secondary Endpoint/Variable  ................................ ................................ ....................  11 
2.2.3  Selected Other Secondary Endpoints/Variables  ................................ ................................  11 
2.2.4  Selected Other Endpoints/Variables  ................................ ................................ ..................  11 
2.2.5  Safety Endpoints/Variables ................................ ................................ ................................  13 
3. STUDY DESIGN  ................................ ................................ ................................ ............................  13 
4. SCHEDULE OF ASSESSMENTS AND TREATMENT ASSIGNMENT  ................................ .... 14 
4.1 Schedule of Assessments  ................................ ................................ ................................ ...............  14 
4.1.1  Study Visit Schedule ................................ ................................ ................................ ..........  15 
4.2 Dosage and Administr ation of Study Drug  ................................ ................................ ....................  16 
4.3 Subject Number  ................................ ................................ ................................ .............................  16 
5. ANALYSIS POPULATIONS  ................................ ................................ ................................ .........  16 
6. STATISTICAL METHODOLOGY ................................ ................................ ................................  17 
6.1 Statistical and Analytical Issues  ................................ ................................ ................................ .... 17 
6.1.1  Statistical Methods ................................ ................................ ................................ .............  17 
6.1.2  Baseline Definition  ................................ ................................ ................................ ............  17 
6.1.3  Missing Data and Handling of Dropouts  ................................ ................................ ...........  17 
6.1.4  Conversion of time  interval  ................................ ................................ ...............................  19 
6.1.5  Pooling of Investigator Sites  ................................ ................................ ..............................  19 
6.1.6  Rescue Medications Use  ................................ ................................ ................................ .... 19 
6.1.7  Determination of Sample Size  ................................ ................................ ...........................  20 
6.2 Subject Characteristics  ................................ ................................ ................................ ..................  20 
6.2.1  Subject Disposition  ................................ ................................ ................................ ............  20 
6.2.2  Protocol Deviations  ................................ ................................ ................................ ...........  20 
6.2.3  Demographics and Background Baseline Characteristics ................................ ..................  21 
6.2.4  Treatment Exposure and Drug Accountability  ................................ ................................ .. 21 
6.2.5  Physical Examination  ................................ ................................ ................................ ........  22 
6.2.6  Medical History (excluding Crohn's disease)  ................................ ................................ .... 22 
6.2.7  Prior and Concomitant Medications and Steroids  ................................ ..............................  22 
6.3 Outcome Analysis ................................ ................................ ................................ ..........................  23 
6.3.1  Primary Outcome Analysis  ................................ ................................ ................................  23 
6.3.2  Key Secondary Outcome Analysis  ................................ ................................ ....................  24 
6.3.3  Selected Other Secondary Endpoints/Var iables  ................................ ................................  24 
6.3.4  Selected Other Endpoints/Variables  ................................ ................................ ..................  25 
6.4 Safety Analysis  ................................ ................................ ................................ ..............................  28 
6.4.1  Adverse Events  ................................ ................................ ................................ ..................  28 
6.4.2  Laboratory Parameters  ................................ ................................ ................................ ....... 29 
6.4.3  Vital Signs  ................................ ................................ ................................ .........................  30 
6.4.4  12-Lead ECG  ................................ ................................ ................................ .....................  30 
6.4.5  Uveitis Assessment  ................................ ................................ ................................ ............  30 
  STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
Protocol No. RHB -104-04 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  4 6.5 Changes to Statistical Analysis Methods Planned in the Protocol  ................................ .................  30 
7. ADDITIONAL OTHER EXPLOATORY ANALYSES  ................................ ................................  31 
8. TABLES, LISTINGS, AND FIGURES  ................................ ................................ ..........................  32 
8.1 Tables, Listings and Graphs (TLFs) for Study Report ................................ ................................ ... 32 
9. REFERENCES  ................................ ................................ ................................ ................................  37 
10. Appendix I: Subject Data Migration from RH B-104-01 to RHB -104-04 (eCRF Completion 
Guidelines - Inform)  ................................ ................................ ................................ ................................ ...... 37 
Subject Migration  ................................ ................................ ................................ ............................  37 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 5 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  5 LIST OF ABBREVIATIONS AND DEFINITIONS  
 
Abbreviation  Term  
5-ASA  5-acetyl sa licylic acid  
6-MP  6-mercaptopurine  
AE Adverse Event  
ALT  (SGPT)  Alanine Aminotransferase  
AST (SGOT)  Aspartate Aminotransferase  
ATC  Anatomical –Therapeutic –Chemical  
bid Twice -daily  
BPM  Beats per Minute  
BMI  Body Mass Index  
BUN  Blood Urea Nitrogen  
°C                  Celsius  
C. difficile  Clostridium difficile  
CD Crohn’s Disease  
CDAI  Crohn’s Disease Activity Index  
CDEIS  Crohn’s Disease Endoscopic Index of Severity  
cm Centimeter  
CMH  Cochran -Mantel -Haenszel  
CRA  Clinical Research Associate  
CRF  Case Report Form  
CRO  Contract Research Organization  
CRP  C-reactive Protein  
CSR  Clinical Study Report  
DBP  Diastolic Blood Pressure  
DBP  Diastolic Blood Pressure  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
ET Early Termination  
°F Fahrenhe it  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 6 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  6 Abbreviation  Term  
IBD Inflammatory Bowel Disease  
IBDQ  Inflammatory Bowel Disease Questionnaire  
ICF  Informed Consent Form  
ITT Intent -to-Treat  
kg Kilogram  
L Liter  
lb Pound  
LDH Lactate Dehydrogenase   
MAP  Mycobacterium avium subsp. paratuberculosis  
Max Maximum  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
n Number of Subjects  
Min Minimum  
PCR  Polymerase Chain Reaction  
PCS Physical Component Summary  
QD Once -Daily  
QTc  Corrected Q -T Interval  
QTcF  Corrected Q -T Interval using Fridericia's  Formula  
RHB  RedHill Biopharma Ltd.  
RBC  Red Blood Cell  
SAE  Serious Adverse Event  
SAF Safety Population  
SAP Statistical Analysis Plan  
SAS®  Statistical Analysis System Software  
SBP Systolic Blood Pressure  
SD Standard Deviation  
SES-CD Simple Endosc opic Score for Crohn’s Disease  
SF-36 Short Form -36 Health Survey  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 7 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  7 Abbreviation  Term  
SOC  System Organ Class  
SOP  Standard Operating Procedure  
TB  Mycobacterium Tuberculosis  
TEAE  Treatment -Emergent Adverse Event  
TLFs  Tables, Listings, Figures  
TNF  Tumor Necrosis Factor  
UK United Kingdom  
ULN  Upper Limit of Normal  
US United States  
VF  Ventricular Fibrillation  
WBC  White Blood Cell  
WHO  World Health Organization  
WHO DD  World Health Organization Drug Dictionary coding system   
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 8 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  8 1. INTRODUCTION  
 
Crohn's Disease (CD) is an inflammatory bowel disease  (IBD)  that is serious, debilitating, and 
potentially life -threatening. The disease is  termed a  “disease of the young” because it usually 
strikes children, teens, and young adults. Typically onset is between the ages of 15 to 2 5 years . Its 
inflammation can cause severe pain, diarrhea, and other intestinal problems. CD affects men and 
women equally and appears to show a familial predisposition. Approximately 20 -30% of people 
with CD have a direct blood relative with some form of IBD. World -wide, an estimated 1.4 
million people suffer from CD (700,000 US) and the number of sufferers is growing at a rate of at 
least 1% each year. The disease is now considered to be the second most common chronic 
inflammatory disorder after rheumatoi d arthritis.  
One of the potential causes of CD is thought to be gastrointestinal infection with Mycobacterium 
avium subspecies paratuberculosis  (MAP) and mycobacterial molecules have been shown to 
dysregulate immune signaling pathways as part of the organi sm’s evolved survival strategy. MAP 
has been difficult to isolate from CD patients and it is postulated that it asserts its pathological 
effect either as an infectious agent or by modifying local cytokine responses.  
One of the hindrances to testing for MAP  infection in CD patients is that MAP is a very slow  
growing mycobacterium. MAP shed their cell walls when they infect humans, a tactic that 
enables them to escape identification and attack by human immune system defenses.  
Studies conducted to demonstrate  the presence of MAP noted it in 55.4% (range 16 -92%) of CD 
subjects vs. 8.2% (range of 0 -49%) of control groups across multiple diagnostic specimens e.g. 
blood, tissue and culture. Recent work in Israel, Japan, and Ireland has shown that human tissue 
and white cells can be infected with MAP and this infection results in cytokine production, 
especially TNF -α and therefore indicate s that MAP plays a role in CD.  
Current therapies for the treatment of CD aim towards alleviation of the disease symptoms and 
offer limited efficacy while often causing significant side effects. In addition, the cost of a 
number of these available therapies is prohibitive, thereby providing limited access to some 
patients. As a result, there continues to be a significant unmet need for more effective disease 
management of CD.  
Several studies evaluating antimicrobial treatment directe d at MAP to treat patients with CD have 
been reported. Given their slow growth and periods of latency, treatment of mycobacterial 
diseases require s multiple antibiotics including triple therapy to avoid the development of 
resistance.  
RHB -104 consists of th ree antimicrobial agents with known activity against mycobacteria, i.e.,  
clarithromycin, rifabutin, and clofazimine. The rationale for the development of RHB -104 is to 
demonstrate the efficacy of an antimicrobial therapy consisting of clarithromycin: 95mg,  
rifabutin: 45mg, and clofazimine: 10mg in the treatment of CD patients. These active ingredients 
and doses were selected to maximize therapeutic effectiveness against MAP. The dosing rationale 
of each active ingredient is supported by the following:  
•  prescriber information for each active ingredient  
•  the study by Selby et al. utilizing a sub -optimal treatment regimen  
•  a long -term, retrospective Australian study where 52 subjects were treated for up to nine 
years on this therapy  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 9 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  9 Subjects who have completed  26 weeks of blinded study drug administration in the RHB -104- 
01 study (MAP US) and remain out of remission with CDA I ≥150 will be eligible for 
participation  in this study designed to offer open label therapy with active RHB -104. 
 
2. STUDY OBJECTIVES AND ENDPOINTS  
 
2.1 Study Objectives  
 
2.1.1 Primary  Objective  
 
The primary objective is to estimate the remission rate, defined as a CD AI score of less than 150, 
at 16 weeks after the initiation of the open -label phase.  
 
2.1.2  Secondary Objective  
 
 The secondary objective is to estimate the response rate of patients, defined by a reduction of 
CDAI score of ≥100 points at week 16 after the init iation of the open -label phase.  
 
2.1.3 Selected Other Secondary Objectives  
 
1.    To estimate the average duration of remission among participants . 
2.  To estimate the average time to first response among participants .  
3.  To estimate the average duration of response am ong participants .  
4.  To estimate the proportion of participants who maintain a state of remission from week 16 
through week 52 .  
 
2.1.4 Selected Other Objectives  
 
MAP Detection:  
 
1.    To estimate the proportion of subjects with a MAP positive blood PCR assay at  baseline 
(week 0 of the open label phase) .  
2.  To estimate the proportion of subjects with a change in MAP blood PCR assay status  after 16 
weeks of treatment compared to baseline (week 0 of the open label phase) . 
3.  To estimate the proportion of subjects with a c hange in MAP blood PCR assay status  after 52 
weeks of treatment compared to baseline (week 0 of the open label phase) . 
4.    To make sequential comparisons of MAP blood PCR assay results per subject . 
5.    To estimate the proportion of enrolled subjects with a M AP positive blood culture at  baseline 
(week 0 of the open label phase) . 
6.    To estimate the proportion of subjects with a change in MAP blood culture status after  26 
weeks of treatment compared to baseline (week 0 of the open label phase) . 
7.    To estimate th e proportion of subjects with a change in MAP blood culture status after  52 
weeks of treatment compared to baseline (week 0 of the open label phase) . 
 
Because the buffy coat is the actual component of blood that is cultured, MAP blood culture 
should be con sidered  equivalent to MAP buffy coat culture. Because the development of  a MAP 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 10 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  10 blood PCR assay is still in progress, MAP detection objectives 1 -4 will comprise  the contents  of a 
later report  and will not be addressed in tables, listings, or figures of this  clinical study report .  
 
Endoscopic Changes in Those Subjects Who Undergo Colonoscopy:  
 
8.    To estimate the change from baseline in the mean Crohn’s Disease Endoscopic Index  of 
Severity (CDEIS) after 16 and 52 weeks of treatmen t).  
9.  To estimate the change from baseline in the total Simple Endoscopic Activity Score  weeks 
(SES -CD) after 16 and 52 weeks of treatmen t. 
10.  To make a comparison of success rates of (ΔCDEIS and SES -CD) defined by 25% and 50% 
improvement s. 
11.   To estimate the correlation between the chan ge from baseline in the endoscopic index 
(ΔCDEIS) and the clinical index (ΔCDAI) after 16 and 52 weeks of treatment.  
12.   To make a comparison of success rates of (ΔCDEIS) defined by 25% and 50%  improvements 
and CDAI defined remissio n. 
13.   To make a comparison  of success rates of (ΔCDEIS) defined by 25% and 50%  improvements 
and CDAI defined re sponse.  
14.   To make a comparison of success rates of (Δ SES-CD) defined by 25% and 50%  
improvements and CDAI defined remissio n. 
15.   To make a comparison of success rates of (ΔS ES-CD) defined by 25% and 50% 
improvements and CDAI defined response.  
 
2.1.5 Safety Objective  
 
Assess the safety impact of treatment with RHB -104. 
 
2.2 Outcomes/ Endpoints  
 
The outcome en dpoints for summaries  by treatment from  the parent study ( RHB-104 treatment 
and Placebo ) and overall are grouped into 4 families  based on level of objectives : (i) primary 
endpoint; (ii) key secondary endpoint ; (iii) selected other s econdary endpoints; and (iv) selected 
other endpoints.   
 
2.2.1 Primary Endpoint/ Variable : Remission  
 
In gene ral use of rescue medication is considered as treatment failure (not achieving remission or 
response) if there are any new use of rescue medication to treat CD or increased rescue 
medication dose from baseline prior to any remission or response assessment.   Please refer to 
section 6.1. 6 for more details .  
 
The primary variable is the proportion of subjects who experienced remission at Week 1 6 after 
the initiation of open -label phase , where remission is defined as a subject having a Crohn’s 
Disease Activity Index (CDAI) score of < 150.  Subjects who have a Week 1 6 CDAI 
measurement ≥ 150 or who do not h ave a CDAI measurement at Week 1 6 will be classified as not 
having achiev ed remission  at that time point .  Initiation of open -label phase is the first dosing 
time of open -label phase and from here and after it would be reference as initiation.  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 11 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  11 The CDAI is used to assess the activity of CD; higher scores indicate more active disease.  
 
2.2.2 Key Secondary Endpoint/Variable  
 
The k ey secondary variable  is the p roportion of  subjects  who experienced response a t week 1 6 
after initiation , where response is de fined as reduction from baseline of ≥100 in CDAI score.  
Subjects who have a change from baseline to week 1 6 in CDAI score which is not a reduction of 
≥ 100 or who do not have a change from baseline to week  16 in CDAI score will be classified as 
not having  experienced response  at that time point . 
 
2.2.3 Selected Other Secondary Endpoints/Variables  
 
• Time to remission – Number of weeks after initiation  that a subject first records a state of 
remission ( CDAI score < 150 ). It will be calculated as the date on which r emission is first 
observed minus the date of the first dosing date plus 1 day, divided by 7.  For subjects 
still on study and not achieved remission at the time of assessment, time to remission will 
be censored at the date of the last assessment of CDAI sc ore.   
• Duration of remission – The number of weeks the subject is in remission (CDAI score < 
150). It will be calculated as the first date following remission at which CDAI is ≥150 
minus the date of remission, plus 1 day, divided by 7.  Those subjects who experienced 
remission and continue to be in remission at the time of their last CDAI assessment will 
be censored at the date of their last CDAI assessment.  Duration of remission will be 
calculated only for patients achieving remission.  
• Time to response – Number of weeks after initiation that a subject first achieves a state of 
response (a reduction from baseline of ≥100 in CDAI score). It will be calculated as the 
date on which response is first observed minus the date of the first dose , plus 1 day, 
divided by 7.  For those subjects  who have  not experienced response, time to response 
will b e censored at the date of the last assessment of CDAI score.   
• Duration of response – Time in weeks that a subject is in a state of response  (a reduction 
from baseline of ≥ 100 in CDAI score). It will be calculated as the first date following 
response at w hich the reduction from baseline in CDAI is <100 minus the date of 
response, plus 1 day, divided by 7.  Those subjects who experienced response and 
continue to be in response at the time of their last CDAI assessment will be censored at 
the date of their l ast CDAI assessment. Duration of  response will be calculated only for 
patients achieved response.  
• Proportion of subjects experienced maintenance of remission (CDAI score < 150) from 
week 16 through week 52.  Subjects experiencing a CDAI score ≥ 150 at any visit time 
point assessment between week 16 and week 52 or have no CDAI measurement week 16 
or week 52 will be considered as having not achieved maintenance of remission . 
 
2.2.4 Selected Other Endpoints/Variables  
 
2.2.4.1  Map Detection Endpoints/Variable  
 
Mycobacterium  avium subsp. paratuberculosis  (MAP) detection p arameters include the following 
with baseline defined as week 0 of the open label phase:  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 12 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  12 • Proportion of subjects with positive MAP buffy coat  culture at baseline , weeks 26 and 52 . 
 
• Proportion of s ubjects with a change in MAP buffy coat  culture after 2 6 and 52  weeks of 
treatment compared to baseline . 
 
 
2.2.4.2  Endoscopic Change Endpoint/ Variables  
 
• Change from baseline to week 1 6 and 52  in Crohn’s Disease Endoscopic Index of 
Severity (CDEIS)  and Simple Endos copic Score for Crohn’s Disease (SES -CD). The 
CDEIS and SES -CD are endoscopic scoring systems for the assessment of CD . 
 
• Success rate by 25% improved in CDEIS from baseline  to week 16 and 52 .  Success  is 
achieved if the CDEIS score is decreased by 25%.  
 
• Success rate by 50% improved in CDEIS from baseline  to week 16 and 52 . Success  is 
achieved if the CDEIS score is decreased by 50%.  
 
• Success rate by 25% improved in SES -CD from baseline  to week 16 and 52 .  Success  is 
achieved if the SES -CD score is decreased by 25%.  
 
• Success rate by 50% improved in SES -CD from baseline  to week 16 and 52 . Success  is 
achieved if the SES -CD score is decreased by 50%.  
 
• Comparison of success rate of by 25% and 50% improved in CDEIS  from baseline  to 
week 16 and 52 vs CDAI defined re mission.  
 
• Comparison of success rate of by 25% and 50% improved in CD EIS from baseline to 
week 16 and 52 vs CDAI defined response.  
 
• Comparison of success rate of by 25% and 50% improved in SES -CD from baseline  to 
week 16 and 52 vs CDAI defined remission.  
 
• Comparison of success rate of by 25% and 50% improved in SES -CD from baseline  to 
week 16 and 52 vs CDAI defined response.  
 
2.2.4.3  Health Related Quality of Life Endpoint/ Variables  
 
• The Short Form -36 Health Survey (SF -36) domain  and component  scores at week 16 and  
52.   
 
• Change from baseline in the total IBDQ score to week 16 and 52.   Inflammatory Bowel 
Disease Questionnaire (IBDQ) score is designed to measure effects of subject’s 
inflammatory bowel disease on their daily functions and quality of life during last 2  
weeks.   
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 13 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  13 2.2.4.4  Markers of Inflammation Endpoint/ Variables  
 
Inflammation parameters include the following : 
 
• Change from baseline in C -reactive protein  (CRP)  
• Change from baseline in fecal calprotectin  
 
2.2.5 Safety Endpoints/Variables  
 
Safety p arameters include the fol lowing:  
 
• Incidence of a dverse events  
• Laboratory parameters (hematology, chemistry , urinalysis ) 
• Clostridium difficile toxin  
• Vital signs  
• ECG  
• Physical examination  
• Concomitant medications  
 
3. STUDY DESIGN  
 
This is an open label, multicenter, Phase III, study des igned to evaluate the efficacy and  safety of 
RHB -104 to treat subjects with active CD as defined by CDAI ≥ 150 despite 26  weeks of 
treatment with study drug in RedHill Biopharma Study RHB -104-01. RHB -104 consists of 3 
antibiotics with activity against Myco bacterium avium subsp. Paratuberculosi s (MAP), a 
potential cause of CD. Eligible subjects with active CD who have completed 26  weeks of study 
drug as part of the RHB -104-01 study will receive up to 52 weeks of open  label RHB -104. 
Subjects enrolled in the o pen label study may have current CD therapies  adjusted or withdrawn as 
clinically indicated by their local investigator after 8 weeks of  open label RHB -104 treatment. 
Sites should begin tapering steroids upon completion of 4  weeks of RHB -104 treatment with  the 
goal of being steroid free by week 14 – Refer to  Appendix 13  of protocol.  
 
MAP are slow growing mycobacteria without a proven antibiotic treatment, and the duration  of 
antibiotic treatment required to achieve remission in subjects with CD caused by MA P is believed 
to be approximately 16 -26 weeks. Subjects with response at week 26 may  ultimately achieve 
remission at a later time point with continued treatment for MAP.  Similarly, some subjects may 
achieve response or achieve remission prior to week 26.  This study is designed to assess 
response, remission, and maintenance of remission in  subjects on open label RHB -104 through 
week 52, as well as corticosteroid free remission  at week 16.  
 
Blood samples will be collected at Screening and at every visit after  the initial 8 weeks of  
treatment to test for MAP in the serum using a polymerase chain reaction (PCR) assay.  Similarly, 
MAP cultures will be prepared from whole blood collected at Screening and at  weeks 16, 26 and 
52. 
 
Safety of the fixed -dose combination  product, RHB -104, will also be assessed.  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 14 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  14 Colonoscopy will be done in consenting subjects at baseline and after 16 and 52 weeks of open 
label RHB -104 to assess for mucosal  healing as well as MAP status via PCR and culture.  
 
 
4. SCHEDULE OF ASSESSMENTS  AND TREATMENT ASSIGNMENT  
 
4.1 Schedule of Assessments  
 
Appendix 1 provides reference information from eCRF guidelines about subject data migration 
from the parent study.  
 
 
The study schedule is summarized in the study visit schedule table  on next page .  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 15 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  15  
4.1.1 Study Vis it Schedule  
 
 

 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 16 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  16  
 
4.2 Dosage and Administration of Study Drug  
 
The target dose of RHB -104 is 5 capsules administered bid. In order to reach this target with 
minimal adverse effects, subjects who received placebo during the RHB -104-01 study will be 
titrated up  over the first 4 weeks of treatment, and the dose will remain stable thereafter. Subjects 
who received RHB -104 will continue to receive RHB -104. In order to maintain blinding in the 
RHB -104-01 study all subjects will receive 5 blinded capsules bid for the  duration of the RHB -
104-04 study as detailed below. The study drug will be taken with food. Subjects who fail dose 
escalation to 5 capsules bid will be considered treatment failures and withdrawn from the study.  
 
Blinded bid Dose Titration and Maintenance  Dosing in RHB -104-04 is  
 
 
4.3 Subject Number  
 
Subjects will maintain the identification number that was assigned in RHB -104-01.    
 
5. ANALYSIS POPULATIONS  
 
All subjects who signed informed consent will be included in the disposition table counts.  
The followi ng populations will be used for data analysis.  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 17 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  17 The Intent -to-Treat (ITT) Population : The ITT population is defined as all subjects  who are 
enrolled in this open -label study and signed the consent form. Efficacy endpoint analyses  will be 
based on ITT popul ation or specified otherwise .  
 
The Safety Population  (SAF) : The safety population includes subjects who receive d any amount 
of study medication. The safety analyses will be based on the SAF population.   
 
6. STATISTICAL METHODOLOGY  
 
6.1 Statistical and Analytica l Issues  
             
6.1.1 Statistical Methods  
 
In general , if there is disagreement between this SAP and the statistical methods outlined in the 
protocol, the SAP would supersede the protocol.  
 
Descriptive statistics summary results will be produced and presen ted for all  the data collected on 
the different assessments that include demographics, baseline characteri stics, concomitant 
medications, outcome , and safety endpoints . Continuous data summary descriptive statistics  will 
includ e the number of observations,  means, standard deviations, medians, and ranges.  
Categorical variables will be summarized with frequencies and percentages  or specified 
otherwise .  
 
In the parent study, there was one randomization stratification factor, use of protocol permitted 
anti-TNF agents (yes/no).   In the current study, treatment comparisons will be performed without 
taking this stratification factor into consideration  unless  specified otherwise .   
 
All statistical analyses will be performed using SAS statistical software (Versio n 9.4 or an 
updated latest higher version available at the time of analysis ).  Adverse events will be coded 
using the most recent MedDRA version available at the time of analysis. Concomitant 
medications will be coded using the most recent version of Worl d Health Organization (WHO) 
Drug dictionary . The actual version of each dictionary will be footnoted in the respective outputs.  
 
6.1.2 Baseline Definition  
 
For subject who received any dose of study drug, baseline is the last non-missing result  prior to 
first dos e including the data collected during the parent study for SES -CD, CDEIS, Calprotectin, 
CRP and all lab assessment .  For subjects who are enrolled in to this open -label study but never 
received any study drug, baseline is  either assessment collected at base line visit if available or 
screening visit  or as specified otherwise .   
 
For fecal calprotectin , the baseline is the last available assessment up to day 3.  
 
6.1.3 Missing Data and Handling of Drop outs 
 
All available outcome  and safety data will be included in da ta listings and tabulations.  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 18 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  18 CDAI Missing Data:  
 
The computation of CDAI requires 7 days of consecutive diary daily data. For subjects with 
CDAI diary data reported that is less than 7 days  of data , the reported data will be standardized to 
7 days by dividing  the sum of CDAI  score over the number of days of data by total number of 
days of reported data multiplied by 7 .  If less than 4 days of diary data is available, the subject 
will be categorized as a non -responder and the CDAI score will be considered missing. As 
specified in section 2.2 , subjects with missing assessment will be assumed to not be in a state of 
remission /success for each scheduled visit (week 16, 26, or 52) .   
 
Handling of missing date information for AEs:  
The term missing date  refers to  a completely missing date or to partial date where  month or/and 
day or/and year is/are missing , e.g. missing month/day/year. Missing start and end dates will be 
imputed conservatively, i.e. missing values will be imputed in such a way that the duration of  the 
AE is considered with the longest possible duration . The missing start date and end date of AE 
will be imputed for the purpose of defining treatment emergent adverse events (TEAE) and for 
assigning events to treatment periods using the following defin itions :  
 
(i)  Adverse Event Start Date:  
Event Missing Day: If Adverse event day is missing but month and year present , then impute the 
1st of the month unless month and year are the same as first dose of study drug then impute day 
first day of dose . 
Event Mi ssing day and month – If adverse event day and month both are missing but year is 
present then impute 1st January unless year is the same as first dose date then impute day and 
month first dose day and month.  
Completely missing – impute first dose date unl ess the end date suggests it could have started 
prior to this in which case impute the 1st January of the same year as the end date.   
 
(ii)  Adverse Event End Date:  
Missing day – If AE day is missing but month and year is present then impute the last day of the  
month.  
Missing day and month – If AE has missing day and month but year is present then impute 31st 
December.  
Completely Missing – Required to  look at whether the AE is still ongoing before imputing a date 
and also when it started in relation to study dru g. If the ongoing flag is missing then assume that 
AE is still present (i.e. do not impute a date). If the AE has stopped and start date is prior to first 
dose date then impute the 1st dose date, if it started on or after first dose date then impute a date  
that is after the last dose date.  
 
(iii) TEAE definition with missing start and stop dates : If the start date of an adverse event is 
incomplete or missing, the event will be assumed to be a treatment -emergent adverse event 
(TEAE ), unless the incomplete st art date (month and/or year) or the stop date (complete or 
incomplete) clearly indicates that the event started prior to dosing. Missing/incomplete 
information will be reported as missing/incomplete in the subject listings.  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 19 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  19 (iv) Adverse event relationship : If the relationship for an adverse event is not recorded, it will be 
assumed to be treatment related in the presentation of the statistical summary of incidence results .  
Missing information will be reported as missing in the subject listings.  
 
(v) Adver se event severity : If the severity of an adverse event is missing, the severity will be 
assumed to be severe when summarizing data. Missing information will be reported as missing in 
the subject listings.  
 
(vi) Non-study medication (concomitant medications , steroids) start and stop dates:  If the start 
and/or stop dates of non -study medication use are incomplete or missing, the use will be assumed 
to be concomitant, unless the incomplete date information clearly indicates that the use stopped 
prior to study medication dosing. Missing/incomplete information will be reported as 
missing/incomplete in the subject listings.  
 
6.1.4 Conversion of time interval  
 
In case time interval was calculated in days and need to be converted into weeks, months or years 
the following conversion factors need to be used:  
 
1 week = 7 days  
1 month = 30.4 days  
1 year = 365.25 days  
 
6.1.5 Pooling of Investigator Sites  
 
All summaries and analysis  will use data pooled across all investigative sites.   
 
6.1.6 Rescue Medications Use  
 
Subjects rescued with t he following treatments or whose baseline doses/regimens are increased to 
treat new or unresolved CD symptoms may remain on the study drug at the discretion of the 
investigator and continue to be assessed at all scheduled study visits:  
•  Oral or rectal 5 -ASA compound s 
• Azathioprine or 6 -mercaptopurine (6 -MP) or methotrexat e 
• Total parenteral nutrition as treatment of C D 
• Systemic or rectal corticosteroid therap y 
• Anti-TNF or other biologic agen t 
 
In analyses  of remission or response , subjects who initiate  new tr eatment  or increase concomitant 
medication to treat CD symptoms will be considered as treatment failures . 
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 20 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  20 6.1.7 Determination of Sample  Size 
 
This study is anticipated to enroll 100 patients. With that number of patients, a two -sided 95% 
confidence interval (us ing the exact Clopper -Pearson method) will have a maximum width of 
0.203 (i.e., +/ - 10.15%) conservatively assuming the measure of interest has proportion of 
successes of 50%. This c onfidence interval will be narrower  for any other possible observed 
propor tion. 
 
6.2 Subject Characteristics  
 
All subject characteristic s data will be listed by subject, and summarized for the ITT population, 
except as noted otherwise.  
 
6.2.1 Subject Disposition  
 
Subject disposition will be presented for all subjects by  parent study treat ment  group  and overall  
for the ITT population. Disposition information that will be summarized will include number of 
subjects who completed the study, number who withdrew prematurely, and reasons for 
withdrawal.  
 
The number and percent of subjects in each of the following categories will be presented.   
• Safety population  
• Subjects completing  weeks 16 and 52  
• Subjects discontinued from the study and by reason of discontinuation.  
 
6.2.2 Protocol Deviations  
 
Subjects  with major protocol deviations will be identifi ed by the medical or clinical data review 
prior to database lock.  The deviations will be summarized by parent treatment group and overall 
based on the safety population. The summary will be grouped into different categories of 
violations such as  below as e xample : 
• Inclusion/Exclusion Criteria Deviations  
• Non-compliance with study procedures  
• Inappropriate intake of prohibited medications  
• Poor compliance with study medications  
• Lost to follow -up 
• Administrative decision of investigator or sponsor  
 
Multiple devia tions can occur in the same subject and thus a subject may be  counted in more than 
one deviation category.    
A listing of subjects with major deviations  will be presented.   
All decisions regarding major deviations w ill be discussed and agreed upon with th e sponsor prior 
to the database lock.   
   
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 21 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  21 6.2.3 Demographics and Background Baseline Characteristics  
 
6.2.3.1  Subject D emographics data . 
 
Demographic s data is collected at time of screening  after informed consent  is obtained  and 
migrated from the parent study (please re fer to Appendix for details) . Demographic s variables 
will be summarized descriptively  for ITT subjects  by parent study  treatment group  and overall 
and will at least include the following variables : 
 
• Age at screening as  continuous variable [Years]  
• Sex 
• Race  
• Ethnicity  
• Height  
• Weight  
• Smoking status and alcohol consumption  
• BMI  
 
6.2.4 Treatment Exposure and Drug Accountability  
 
6.2.4.1  Treatment Exposure  
 
Exposure will be summarized  for the SAF population.  Subjects are instructed to bring their study 
medication and all empty packaging to the clinic visit. Cumulative treatment exposure per subject 
will be calculated as sum of all dosage of treatment consumed. Time on treatment (in days) will 
be calculated per subject as the number of days of study medication intake during the t rial. This 
will be calculated as:  
 
Date of last study medication  administration – Date of first study medication administration  + 1. 
 
Dosing data will be presented descriptively by  parent study  treatment group and overall and also 
presented as subject data listing  for the Safety population.  
 
In addition, treatment duration (RHB -104 or Placebo) of combined parent study and current study 
will be descriptively summarized by parent study treatment group . Combined treatment duration 
in weeks will also be catego rically summarized displaying the number and percentage of patients 
with treatment duration by every 10 weeks and by parent study treatment group.  
 
6.2.4.2  Accountability/Compliance  
 
Drug compliance will depend u pon capsule counts at each visit. Subjects are instr ucted to bring 
their study medication and all empty packages to each clinic visit. Compliance will be assessed 
by capsule counts recorded by each site for each subject. The details of medication used will be 
recorded and reconciled against expected medicat ion use. Compliance will be calculated as the 
reported medication used by subject as p ercentage (%) of expected usage . Summary descriptive 
statistics will be presented for the number and proportion of subjects non -compliant (< 80% 
compliant) for safety pop ulation.  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 22 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  22  
Extent of compliance of each subject data will be presented in subject listing for the SAF 
population.  
 
6.2.5 Physical Examination  
 
Complete p hysical examination  is performed at screening and includes  each subject’s major body 
systems: general appeara nce, head/eyes/ears/nose/throat, neck, lungs, heart, abdomen, 
genitourinary, extremities, neurological, skin, and lymphatics and other. Results (normal, 
abnormal and clinically significant abnormal and not clinically significant) will be tabulated for 
each body system with the number and percentage of subjects .  
 
Number of percent of subjects with significant change in physical examination  from previous 
visit at baseline and subsequent post baseline visits  will be summarized.  
 
6.2.6 Medical History  (excluding Cr ohn's disease)  
 
6.2.6.1  Medical History (excluding Crohn’s disease)  
 
Pre-existing medical c onditions are recorded at screening  on the medical history  eCRF  per 
subject data migration from the parent study ( please refer to Appendix for details) . For e ach 
subject, medical history data will be presented in a data listing.   
 
6.2.6.2  Crohn’s Disease History  
 
Crohn’s disease history is recorded at screening on the history eCRF  per subject data migration 
from the parent study ( please refer to Appendix for details) . Data including steroid status (steroid -
refractory disease or steroid -dependent  disease ) will be presented descriptively by parent study 
treatment group and overall and also presented as data listing . Duration of each condition is  
based on the first dose of study medicat ions administration for the current extension study.  
 
6.2.7 Prior and Concomitant Medications and Steroids  
 
Prior medications will be defined as medications stopped prior to Day 1 of study medication.  
Concomitant medications include medications taken on or after  the first dose of study medication 
as well as medications that started prior to the first dose of study medication and continued after 
the first dose of study medication.  The following algorithm will be used to define prior and 
concomitant:   
 
The medicat ion will be assumed to be prior medication if it cannot be definitively shown that the 
medication did not start or continue during the treatment period.  
If the start date or stop date of a medication is partially missing, the date will be compared as far 
as possible with the date of the start of administration of study drug. The following approach will 
be taken:  
• If the start date of medication is complete and occurs on or after the day of the first dose, 
the medication will be assumed concomitant.  If the s tart date occurs prior to the first 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 23 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  23 dose date but the end date is on or after the first dose date or the medication is recorded 
as ongoing, the medication will be considered concomitant.  
• If the start day is missing but the start month and year are complete , a medication will 
only be excluded as being concomitant if the start month/year is before the month/year of 
study drug administration and if the stop date (either full date, month and year if missing 
day, or year if missing month and day) is before study  drug administration.  
• If the start day and month are missing but the start year is complete, a medication will 
only be excluded as concomitant if the start year is before the year of study drug 
administration and if the stop date (either  full date, month a nd year if missing day, or year 
if missing month and day) is before study drug administration.  
• If the start date is completely missing and the stop date is prior to first dose or completely 
missing, the medication will be assumed to be a prior medication.  
 
All p rior and concomitant medicatio ns recorded on CRF will be mapped to standardized terms 
using the World Health Organization Drug  Dictionary coding system (WHO DD ). The 
Anatomical –Therapeutic –Chemical (ATC) Classification level 2 and preferred term  will be used 
to summarize the data  by treatment group . A subject having the same medication more than once 
will be counted only once in the incidence table for that medication.  For each ATC classification 
and Preferred Term the number and percentage of subject s will be displayed .  Summary tables 
will be presented on SAF population  separately for the following:  
 
• Prior Medications  Use for Crohn’s Disease  
• Prior Medications Use  
• Concomitant Medications Use 
• Prior Biological Agents Use  
• Concomitant Medications Use  for Crohn’s Disease  
• Prior Steroids Use  
• Concomitant Steroids Use  
• Concomitant Steroids Use  for Crohn’s Disease  
• Prior Antineoplastic, Immumosupressive and Biologic Us e 
• Concomitant Antineoplastic, Immumosupressive and Biologic Use  
 
All prior and concomitant medica tions/treatments will be presented in a data listing with dose, 
units, frequency,  route  of administration, indication, start and end dates  for the safety  population . 
A separate Steroids use subject listing may be presented providing the steroid coded ATC 
classification,  preferred te rm, and date.  
 
Any concomitant procedures recorded on CRF will be presented in a data listing with procedure  
name, date and reason.  
  
6.3 Outcome  Analysis  
 
The outcome  analyses will be based  on all ITT subjects .  
 
6.3.1  Primary  Outcome  Analysis  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 24 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  24 The primary outcome  variable  is the proportion of subjects experienc ed remission  at week 1 6. 
95% exact Clopper -Pearson confidence interval (CI) of the proportion of remission will be 
provided within each parent study treatment group and overall, as  well as subgroup by anti -TNF 
agent use. Parent study treatment comparison will be performed using Fisher’s exact test .   
 
For the above primary analysis, subjects with a missing week 16 CDAI will be treated as not 
achieving  remission.  As a sensitivity an alyses, the same analyses will be performed without 
imputation, i.e. sub jects with missing week 16 CDAI  will not be imputed , therefore  it will be 
missing and excluded from analysis.  
 
Logistic regression modeling will be implemented as additional explorator y analysis to assess 
relationships between the primary outcomes and putative effect modifiers. The putative effect 
modifiers include the following patient level biomarker assessment:  
 
• Baseline serum inflammation marker: C -reactive protein (CRP ≥ 2.87 vs . < 2.87 mg/dL )  
• Baseline stool inflammation marker: Fecal calprotectin ( ≥ 250 vs. < 250 mcg/g ) 
• Baseline SES -CD≥6, Fecal calprotectin ≥ 250 mcg/g or CRP≥ 2.87 mg/dL: Yes vs.  No  
 
The logistic regression model includes r emission at week 16 (yes/no) as a function of  parent 
study treatment by baseline biomarker factor . The aim is to identify if the effect of each baseline  
biomarker  factor has significant effect on remission outcome. The analysis will be performed to 
compare parent study treatment group s. Odds  ratio of remission rate (p arent study treatment 
RHB -104 vs. placebo) and 95% CI will be presented using a Forest plot for each baseline 
biomarker level.   Similar plots will be provided for week 16 response and week 52 remissions.  
 
6.3.2 Key Seconda ry Outcome Analysis  
 
The key secondary outcome variable is the proportion of subjects experienced response at week 
16.  95% exact Clopper -Pearson confidence interval (CI) of the proportion of responders will be 
provided within each parent study treatment g roup and overall, as well as subgroup by anti -TNF 
agent use. Parent study treatment comparison will be performed using Fisher’s exact test .   
 
The s ame logistic regression analysis as the primary output variable will also be performed.  
 
6.3.3 Selected Other Seco ndary Endpoints/Variables  
 
6.3.3.1  Time to Event Endpoints/Variables Analysis  
 
The Time to event endpoints that will be analyzed includes:  
• Time to remission  
• Duration of remission  
• Time to response  
• Duration of response  
 
Kaplan Meier survival curves and parameters s howing time -to-first observed response outcome 
will be summarized by parent study treatment , by anti -TNF use and overall . Summary statistics 
that will be presented will include minimum, maximum, the 25th and 75th percentiles, 95% 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 25 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  25 confidence intervals on th e median (using the method of Brookmeyer and Crowley), and 
proportion of the events and censored data.  Parent study treatment comparison will be performed 
using log -rank test.   
 
Kaplan -Meier plots with descriptive summary statistics will be presented.  
 
6.3.3.2  Remission from Week 16 through week 52 
 
Number and p roportion of subjects experienc ing maintenance of remission (CDAI score < 15 0) 
from week 16 through week 52  and the number and proportion of subjects experiencing remission 
at week 16 and week 52 will be provided within each parent study treatment group and overall, as 
well as subgroup by anti -TNF agent use.  95% exact Clopper -Pearson confidence interval (CI) for 
the proportion will also be presented.  Parent study treatment comparison will be performed usi ng 
Fisher’s exact test .   
 
In addition, similar summaries will be provided for remission at week 52 overall and for subjects 
who achieved remission at week 16  
 
Proportion of subjects who achieved the following response will be provided overall and by 
paren t study treatment:  
 
Remission at week 16 plus 50% reduction in CRP  or calprotectin  from baseline  
Remission at week 52 plus 50% reduction in CRP or calprotectin from baseline  
 
6.3.4 Selected Other Endpoints/Variables  
 
6.3.4.1  MAP  Buffy Coat  culture  
 
All summar ies will be  done by parent study treatment and overall.   
 
Number and percent of subjects will be summarized for MAP buffy coat culture  
(positive/negative)  by schedule d visit (baseline, week s 16, 26 and 52), 95% exact Clopper -
Pearson confidence interval (CI) will be provided for the proportion of positive MAP  buffy coat  
culture . 
 
Shift table from baseline to each post baseline visit  (weeks 16, 26 and 52) will be summarized.    
 
6.3.4.2  Endoscopic Assessment Based on CDEIS  and SES-CD  
 
The Crohn’s Disease Endoscopic Index of Se verity (CDEIS) is a validated quantitative measure 
of disease severity upon endoscopy. The score ranges from 0 -44 based upon the extent and 
severity of inflammation and ulcers seen during endoscopy of the colony. A response is a 
decrease  in score from base line. 
 
The Simple Endoscopic Score for Crohn’s Disease (SES -CD) is a validated quantitative measure 
of disease severity upon endoscopy  that is based on four endoscopic variables (presence and size 
of ulcers, extent of ulcerated surface , extent of affected surface , and presence of narrowing ). Each 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 26 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  26 variable is assessed in each of the five ileocolic segments: rectum, sigmoid and left colon, 
transverse colon, right colon, and ileum. Each of the four SES -CD variables is scored from 0 to 3, 
with the sum of the sc ores for each variable ranging from 0 to 15  (Total SES -CD score range 0–
60). 
 
CDEIS data are presented in data listing only.  
 
The SES -CD total scores by visit (baseline and weeks 16 and 52 ) and change from baseline 
scores to week 16 and 52 will be summari zed descriptively for subjects who consent to undergo 
colonoscopy  by parent study treatment and overall . The summary statistics include number of 
observations, mean  with 95% CI , standard deviation, median,  inter-quartile ranges,  minimum, 
and maximum . 
 
Numb er and p roportion of subjects  who achieved success defined below and corresponding 95% 
exact Clopper -Pearson C I for the proportion will be provided .  
 
• by 25% improved in SES -CD from baseline to week 16 and 52.  Success is achieved if 
the SES -CD score is de creased by 25%.  
 
• by 50% improved in SES -CD from baseline  to week 16 and 52 . Success is achieved if the 
SES-CD score is decreased by 50%.  
 
Paired response between each of above defined improvement and corresponding CDAI remission 
(<150) at each visit will b e compared using exact McNemar’s test.  Similarly , paired response 
between each of above defined improvement and corresponding CDAI response (>=100% 
decrease from baseline) at each visit will be compared using exact McNemar’s test . 
 
6.3.4.3  Quality of Life Assessm ent: SF -36 Questionnaire Total Score  
 
The SF -36 Health Survey is a self -administered, 36 -item questionnaire designed to measure 8 
domains of functional health status and well -being. For this study, the questionnaire data is 
collected at baseline, week 26 a nd week 52. The S F-36 instrument guidelines will be use d to 
assess  and summarize the  overall health status. The SF -36 consists of 8 scaled scores  with range 
0-100 with higher score indicating better health . The 8 sections or domains are:  
 
• Vitality  
• Physical  functioning  
• Bodily Pain  
• General Health Perceptions  
• Physical Role Functioning  
• Emotional Role Functioning  
• Social Role Functioning  
• Mental Health  
 
There are also two component scores. The Physical Component Summary Score is a composite of 
the Physical Functio ning, Role Functioning, Bodily Pain and General Health scales. The Mental 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 27 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  27 Health Component Summary Score is a composite of the Vitality, Social Functioning, Role -
Emotional and Mental Health scales .   
 
All above -mentioned domain and component scores will be provided by QualityMetric  and will 
be presented for data listings .  
 
6.3.4.4  Inflammatory Bowel Disease Questionnaire ( IBDQ ) Score  
 
IBDQ is used to assess IBD status. IBDQ is a valid  and reliable quality of life instrument that 
incorporates social, systemic and e motional symptoms together  with bowel -related symptoms 
into activity index.  The IBDQ includes 32 questions on 4 areas of health -related quality of life:  
 
Bowel Systems (10 questions : 1, 5, 9, 13, 17, 20, 22, 24, 26, 29 ),  
Emotional  Health Function (12 que stions : 3, 7, 11, 15, 19, 21, 23, 25, 27, 30, 31, 32 ),  
Social Function (5 questions : 4, 8, 12, 16, 28 ), and  
System Function (5 questions : 2, 6, 10, 14, 18 ). Each item is rated on 7 -point Likert scale (higher 
scores equate to higher quality of life).  
 
A total IBDQ score is calculated as sum of all 32  scores and the total ranges from 32 to 224. If 
more than 4 questions are missing,  then total scores will not be calculated.  If 4 or fewer questions 
are missing, then missing questions will be imputed by the mean of the rest of available question  
scores.  
 
Summary descriptive statistics including number of observations, mean  with 95% CI , standard 
deviation, median,  inter-quartile ranges,  minimum, and maximum  will be presented in tables  and 
bar graph  for the act ual and change from baseline scores for IBDQ total score  by scheduled visits 
(week 16 and week 52) .  The summaries will be done by parent study treatment and overall.   
 
6.3.4.5  Serum Marker of Inflammation : C-reactive Protein  (CRP)   
 
The CRP is used as mark er of inflammation . The CRP level data collected at  baseline, week 16, 
26, 39 and 52  will be used to assess inflammation at baseline  and at different visits post-baseline. 
Summary descriptive statistics for the actual observed and change from baseline will includ e 
mean  with 95% CI , standard deviation, median,  inter-quartile ranges  and range  for each parent 
study treatment  and overall  by visit.   
 
In addition, the CRP level will be classified into two categories: “Normal ( ≤ 0.999 mg/dL )” and 
“High ( > 0.999  mg/dL )”.  Summary results will show number of patients and proportion (%)  
along with 95% exact Clopper -Pearson  CI with “Normal level” and with “High Level” by parent 
study treatment group and overall by visit .  Shift table s from baseline to each post baseline  visit 
will also be presented.   
 
6.3.4.6  Stool Marker of Inflammation: Fecal calprotectin  
 
The fecal calprotectin is used as mark er of inflammation . The level of fecal calprotectin  data 
collected at different visits will be used to assess inflammation at baseline and at different visits 
post-baseline  (weeks 16, 26 and 52) . Summary descriptive statistics for the actual observed and 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 28 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  28 change from baseline will include mean  with 95% CI , standard deviation, median,  inter-quartile 
ranges  and range for each parent study treatm ent group and overall  by visit.  
 
In addition, fecal calprotectin  will be classified into two categories: “Normal (≤ 162.9  mcg/g )” 
and “High (> 162.9  mcg/g )”.  Summary results will show number of patients and proportion (%)  
along with 95% exact Clopper -Pearson  CI with “Normal level” and with “High Level” by 
treatment group by visit. In addition , shift table s from baseline to each post baseline  visit will also 
be presented.   
 
6.3.4.7  Additional Endpoints : CDAI score and PRO -2  
 
PRO-2 is defined as 7 x (mean daily number of liquid or very soft stools)  + 7 x (mean daily 
abdominal pain sc ore) based on CDAI assessment. CDAI and PRO -2 scores will be summarized 
descriptively by visit.    
 
6.4 Safety Analysis  
 
All summarization of safety data will be based on the safety population  by parent study treatment 
group and overall . 
 
6.4.1 Adverse Events  
 
Each verbatim adverse event (AE) term recorded during the study will be mapped to a system 
organ class and preferred term using the current MedDRA Dictionary.  
 
A treatment -emergent AE (TEAE) is defined as an AE that based on start date information 
occurred aft er the first study drug administration or an AE that started before the first study drug 
administration but worsened in severity (i.e., became more severe) after administration of the 
study drug.  
 
Treatment related adverse events will be defined as the ad verse events for  which the investigator 
indicates the relationship to study drug a s possible, probable, or definite . If the relationship to 
study drug for an AE is not recorded, it will be assumed to be treatment related in the summary 
tables. Similarly, i f severity of an AE is missing, the severity will be summarized as severe . 
 
A by -subject listing of all AEs (including non -treatment -emergent AEs) will be provided and will 
include all AE data recorded on the eCRF. All summaries of AEs will present the num ber and 
percent of subjects reported events by system organ class and preferred term and  by treatment 
group. If a subject has multiple occurrences of an AE, the subject will be counted only once in the 
respective AE. 
 
For summaries of adverse events by max imum severity  or maximum  relationship , if a subject has 
multiple occurrences of an AE, the subject will be counted only once for the respective Preferred 
Term at the maximum severity  or maximum relationship . 
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 29 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  29 An overall summary  table  by treatment and overa ll of AEs , SAEs , TEAEs, Serious TEAEs, 
treatment -related TEAEs, treatment -related SAEs, TEAEs leading to study discontinuation and 
study deaths  will be provided  using number and % of subjects . 
 
Summar y tables by treatment and overall will be provided by SO C and preferred term  for each of 
the following types of AEs:  
• All Treatment emergent AEs   
• Study Drug  related treatment emergent AEs  
• Treatment emergent AEs by maximum severity  
• Treatment emergent AEs leading to study discontinuation  
• Serious Treatm ent emergent  AEs (SAEs)  
• Treatment -related serious AEs  
• Treatment emergent AEs leading to Death  
 
The following listings will be provided:  
• All AEs  
• Treatment related AEs  
• AEs leading to study discontinuation  
• SAEs  
• Deaths  
 
All study d eaths will be listed using date and caus e of death along with autopsy results as entered 
on the Death CRF.  
 
6.4.2 Laboratory Parameters  
 
Laboratory assessments will include:  
 
Bioc hemistry :  total protein , gamma  glutamyl  transferase (GGT  ), lactate dehydrogenase (LDH) , 
sodium , potassium , chloride , magnesium , glucose , total bilirubin , AST(SGOT) , ALT(SGPT) , 
alkaline phosphatase , amylase , albumin , BUN , calcium , creatinine , uric acid , HCO 3, total 
cholesterol , creatinine phosphokinase , and i norganic phosphorous . 
 
Hematology :  RBC count, hemoglobin, hematocr it, platelet count, WBC count, WBC differential . 
 
Urinalysis : Pregnancy, pH (dipstick), specific gravity (dipstick), glucose (dipstick), protein 
(dipstick), ketones (dipstick), blood (dipstick), Nitrites , Leucocytes and s ediment microscopy  if 
indicated by the dipstick . 
 
Laboratory results will be presented in listings in measured units and summaries in conventional 
units.  
 
Continuous laboratory values will be summarized descriptively by treatment group over time for 
each visit and as change from baseline t o each visit. Categorical laboratory values will be 
summarized as the number and percentages of subjects in each  category by treatment group over 
time for visit. 
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 30 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  30 Laboratory parameters will also be summarized in shift tables by treatment, to determine the 
number and percentage of subjects  with measurements classified in a particular category at each 
post-baseline visit with reference to the same classification at baseline.  Bioc hemistry and 
hematology parameters (which are continuous in nature) will use the  classifications of low, 
normal, and high relative to normal ranges, whereas appropriate categories will be selected for 
urinalysis parameters (which are categorical in nature), for example, normal and abnormal.  
 
Subjects missing a value at any time point will be excluded from the summary statistics for that 
time point. If a subject has more than one value at any time point, then the latest non missing 
value will be used  for summarization . All values will be presented in the data listings.  
 
Listings of all  individual laboratory data, indicating any values out of the normal range will be 
produced.  A listing of lab parameter values flagged as abnormal will also be provided.    
 
6.4.3  Vital Signs     
 
Vital signs includ e the following:  
• Supine systolic b lood pressure  (SBP)   
• Supine diastolic b lood pressure  (DBP)   
• Supine pulse rate   
• Respiratory rate   
• Temperature  
• Height  
• Weight  
• BMI  
 
Vital signs are recorded at baseline and at different visits post -baseline. Actual and change from 
baseline values will be summariz ed using d escriptive statistics  by visit and treatment group . The 
mean, standard deviation, median, and range will be used to summarize the data. For each 
subject, vi tal signs data will be presented in a data listing.  
 
6.4.4 12-Lead ECG  
 
Study investigators will record ea ch subject ECG data. The significance and interpretation of each 
ECG finding and a ssessment s of the QTc and other ECG intervals will be made by the ECG 
specialized Lab. All ECG data will be presented in the subject data listing s with annotations 
indicating  any abnormal  values .  For analysis details and presentation of the ECG findings , a 
specialized independent technical report will be produced by  different specialized expert.   
 
6.4.5 Uveitis Assessment   
 
Results from Uveitis assessments will be listed and summa rized as the number and percentage of 
subjects with Uveitis suspected (yes or no), and if suspected, with Uveitis confirmed (yes or no).  
 
6.5 Changes to Statistical Analysis  Methods Planned in the Protocol  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 31 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  31 Because the buffy coat is the actual component of bl ood that is cultured, MAP blood culture 
should be considered equivalent to MAP buffy coat culture. Because the development of a MAP 
blood PCR assay is still in progress, MAP detection objectives 1 -4 will comprise the contents of a 
later report and will not  be addressed in tables, listings, or figures of this clinical study report.  
 
Change from baseline in the Short Form -36 Health Survey (SF -36) total score  have been  removed 
to be consistent with parent study.   Summary of domains are removed in SAP.  
 
Correl ation s between the change from baseline in SES-CD and the change from baseline in CDAI  
to week 16 and 52 are not included in SAP.  
 
 
7. ADDITIONAL OTHER EXPLOATORY ANALYSES  
 
Other exploratory subgroup analyses to characterize safety and efficacy activities of HRB -104 
may be conducted. These additional exploratory analyses will be decided at the time of final data 
analysis  if deemed necessary . 
 
   
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 32 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  32 8. TABLES, LISTINGS, AND FIGURES  
 
The intended layouts for unique summary tables , listings, and figures (TLFs)  are pre sented in a 
separate document. However, it may be necessary to change the table layouts, as appropriate, 
upon review of the data available  without modifying the SAP text .   
 
8.1 Tables, Listings and Graphs ( TLFs ) for Study Repo rt   
 
List of Tables  and Graphs : 
 
Table Number  Title  
Analysis Populations and Disposition  
Table 14.1.1.1  Subject Disposition : All screened subjects  
Table 14.1.1.2  Major Protocol Deviations : Safety  Population  
 
Demographics and Baseline Characteristics  
Table 14.1.2.1  Demographics and B aseline Characteristics: : Intent -to-Treat Population  
Table 14.1.2. 2 Physical Examination at Baseline : Safety  Population  
 
Medical History  
Table 14.1. 3 Crohn's Disease History : Safety  Population  
 
Prior and Concomitant Medications  
Table 14.1. 4.1 Prior M edications  Use: Safety  Population  
Table 14.1. 4.2 Concomitant Medications Use: Safety  Population  
 
Treatment Exposure and Compliance  
Table 14.1. 5.1 Study Drug Exposure : Safety  Population  
Table 14.1. 5.2 Treatment Compliance: Safety  Population  
Table 14.1 .5.3 Combined Study Drug Exposure  with Parent Study: Safety  Population  
 
Primary and Key Secondary Outcome  Endpoint  
Table 14.2.1.1  Primary Endpoint - Remission at Week 16: Intent -to-Treat Population  
Table 14.2.1. 2.1 Remission at Week 16 for Subjects with  Baseline SES -CD ≥ 6 or 
Calprotectin(mcg/g)≥ 250 or CRP(mg/dL) ≥ 2.87 : Intent -to-Treat Population  
Table 14.2.1. 2.2 Remission at Week 16 and at least 50% Reduction in CRP  or Calprotectin  from 
Baseline : Intent -to-Treat Population : Intent -to-Treat Population  
Table 14.2.1. 2.3 Remission at Week 16 and at least 50% Reduction in CRP or Calprotectin from 
Baseline for Subjects with Baseline SES -CD ≥ 6 or Calprotectin(mcg/g)≥ 250 or 
CRP(mg/dL) ≥ 2.87 : Intent -to-Treat Population  
Table 14.2.1.2. 4 Remission at Week 1 6 by Baseline MAP Buffy Coat Culture  Status  : Intent -to-
Treat Population  
Table 14.2.1.2. 5 Remission at Week 16 by Week 16  MAP Buffy Coat Culture  Status : Intent -to-
Treat Population  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 33 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  33 Table 14.2.1. 3 Sensitivity Analysis - Remission at Week 16: Intent -to-Treat Population  
Table 14.2.2  Key Secondary Endpoint - Response at  Week 16: Intent -to-Treat Population  
Figure 14.2.1.1  Forest Plots  of Week 16 Remission Odd s Ratio of Parent Study Treatment RHB -
104 vs Place by Selected Baseline Biomarker Categories : Intent -to-Treat 
Population   
Figure 14.2.2  Forest Plots of Week 16 Response Odd s Ratio of Parent Study Treatment RHB -
104 vs Place by Selected Baseline Biomarker Categories: Intent -to-Treat 
Population  
 
Selected Other  Secondary Outcome  Endpoint s 
Table 14.2. 3.1 Remission from Week 16 to Week 52 : Intent -to-Treat Population  
Table 14.2.3.2  Remission at Week 16 and Week 52: Intent -to-Treat Population  
Table 14.2.3. 3.1 Remission at Week 52: Intent -to-Treat Population  
Figure 14.2.3.3.1  Forest Plots of Week 52:Remission Odds Ratio of Parent Study Treatment RHB -
104 vs Place by Selected Baseline Biomarker Categories: Intent -to-Treat 
Population  
Table 14.2. 3.3.2 Remission  at Week 52  for Subjects with Baseline SES -CD ≥ 6 or 
Calprotectin(mcg/g)  ≥ 250 or CRP  (mg/dL) ≥ 2.87  
Intent-to-Treat Population  
Table 14.2.3 .3.3 Remiss ion at Week 52  and at least 50% Reduction in CRP  or Calprotectin from 
Baseline : Intent -to-Treat Population : Intent -to-Treat Population  
Table 14.2. 3.3.4 Remission at Week 52  and at least 50% Reduction in CRP or Calprotectin from 
Baseline for Subjects with Baseline SES -CD ≥ 6 or Calprotectin(mcg/g)≥ 250 or 
CRP(mg/dL) ≥ 2.87 : Intent -to-Treat Population  
Table 14.2. 3.3.5 Remission at Week 52  by Baseline MAP Buffy Coat Culture  Status : Intent -to-
Treat Population  
Table 14.2.3.3. 6 Remission at Week 52  by Week 52  MAP Buffy Coat Culture  Status : Intent -to-
Treat Population  
Table 14.2.4.1  Time to Remission: Intent -to-Treat Population  
Table 14.2.4.2  Duration of Remission: Intent -to-Treat Population  
Table 14.2.4.3  Time to R esponse: Intent -to-Treat Population  
Table 14.2.4.4  Duration of Response: Intent -to-Treat Population  
Figure 14.2.4.1  Time to Remission Kaplan Mei er Survival Curve: Intent -to-Treat Population  
Figure 14.2.4.2  Duration of Remission Kaplan Mei er Survival Cur ve: Intent -to-Treat Population  
Figure 14.2.4.3  Time to Response Kaplan Mei er Survival Curve: Intent -to-Treat Population  
Figure 1 4.2.4.4  Duration of Response Kaplan Mei er Survival Curve: Intent -to-Treat Population  
 
Selected Other Secondary Outcome  Endpoi nts 
Map PCR Blood Assay and MAP Blood Culture  
Table 14.2. 5.1 Summary of MAP Buffy Coat Culture by Visit : Intent -to-Treat Population  
Table 14.2.5.2  Shift in MAP Buffy Coat Culture from Baseline to Weeks 1 6, 26 and 52  
 
Endoscopic Assessment s 
Table 14.2. 6.1 Baseline and  Change from Baseline to Weeks 1 6 and 52 in SES -CD Total Scores: 
Intent -to-Treat Population  
Table 14.2.6.2  Endoscopic Response: 25% reduction in SES -CD Total S core from baselin e to 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 34 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  34 week s 16 and 52 : Intent -to-Treat Population  
Table 14.2.6.3  Endoscopic Response: 50% reduction in SES -CD Total S core from baselin e to 
week s 16 and 52 : Intent -to-Treat Population  
 
Quality of Life Assessment  
Table 14 .2.7 Inflammatory Bowel Disease Questionnaire  (IBDQ) Score  at Baseline, Week 16 
and Week 52: Intent -to-Treat Population  
Figure 14.2.7 .1 Bar Graphs of IBDQ Total Score at Baseline,  26 and 52 weeks by Treatment 
group: Intent -to-Treat Population  
Figure 14.2.7 .2 Bar Graphs of IBDQ Sub Score at Baseline,  26 and 52 weeks by Treatment 
group: Intent -to-Treat Population  
 
Inflammation Assessment  
Table 14.2. 8.1.1 Summary Serum Marker of Inflammation (CRP) Level: Intent -to-Treat 
Population  
Table 14.2. 8.1.2 Summary Stool Marker of Inflammation Level - Fecal calprotectin: Intent -to-
Treat Population  
Table 14.2. 8.2.1 Proportion of subjects  with CRP Marker of Inflammation Normal/High by Visit: 
Intent -to-Treat Population  
Table 14.2. 8.2.2 Proportion of subjects  with Fecal calprotectin Normal/High by Visit : Intent -to-
Treat Population  
Table 14.2. 8.3.1 Shift  in S erum Marker of Inflammation (CRP)  Status Normal/High from 
Baseline to Week s 16, 26, 39 and Week 52: Intent -to-Treat Population  
Table 14.2. 8.3.3 Shift  in Stool Marker of Inflammation (Fecal calprotectin) Status Normal/High 
from Baseline to Week s 16,  26 and Week 52 : Intent -to-Treat Population  
 
Additional endpoints  
Table 14.2.9.1  Summary of CDAI Score by Visit : Intent -to-Treat Population  
Table 14.2.9.2  Summary of PRO -2 Score by Visit : Intent -to-Treat Population  
 
Adverse Events  
Table 14. 3.1.1.1 Adverse  Event s Incidence  Summary : Safety Population  
Table 14. 3.1.1.2 Adverse Event s Incidence  Summary  by Anti -TNF Use: Safety Population  
Table 14. 3.1.2.1 Treatment -Emergent Adverse Events by System Organ Class and Preferred 
Term : Safety Population  
Table 14. 3.1.2.2 Treatment -Emergent Adverse Events by System Organ Class and Preferred Term  
by Anti -TNF Use: Safety Population  
Table 14.3.1.2. 3 Summary of Treatment -emergent Adverse Events Occurring in at Least 5% of 
Subjects by System Organ Class and Preferred Term in Descending Frequency  
Table 14.3.1.2. 4 Summary of Treatment Related Treatment -emergent Adverse Events Occurring 
in at Least 5% of Subjects by System Organ Class and Preferred Term in 
Descending Frequency  
Table 14. 3.1.3 Treatment -Emergent Adverse Even ts by System Organ Class, Preferred Term, 
and Relationship to Study Medication : Safety Population  
Table 14. 3.1.4 Treatment -Emergent Adverse Events by System Organ Class, Preferred Term, 
and Maximum Severity : Safety Population  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 35 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  35 Table 14. 3.1.5 Treatment -Emergent Adverse Events Leading to Study  Discontinuation by 
System Organ Class and Preferred Term : Safety Population  
Table 14. 3.1.6 Treatment -Emergent Serious Adverse Events by System Organ Class and 
Preferred Term : Safety Population  
Table 14. 3.1.7 Treatme nt-Emergent Serious Adverse Events by System Organ Class, Preferred 
Term, and Maximum Relationship to Study Drug : Safety Population  
Table 14. 3.2.1 Listing  of Subjects with Adverse Events that Led to Death : Safety Population  
Table 14. 3.2.2 Listing Subject s with Treatment -Emergent Serious Adverse Events : Safety 
Population  
Table 14. 3.2.3 Listing Subjects with Adverse Events that Led to Study Discontinuation or Study 
Drug Interruption : Safety Population  
Table 14. 3.2.4 Listing of Subjects with Treatment -Emer gent Adverse Events Related to Study 
Drug : Safety Population  
Table 14. 3.2.5 Listing of Death s: Safety Population  
 
Labs Assessments  
Table 14. 3.4.1 Bioc hemistry Laboratory Data – Observed and Change from Baseline : Safety 
Population  
Table 14. 3.4.2 Bioc hemistry Laboratory Data – Shift from Baseline : Safety Population  
Table 14 .3.4.3 Hematology Laboratory Data – Observed and Change from Baseline : Safety 
Population  
Table 14 .3.4.4 Hematology Laboratory Data – Shift from Baseline : Safety Population  
Table 14 .3.4.5 Urinalysis Laboratory Data – Observed and Change from Baseline : Safety 
Population  
Table 14 .3.4.6.1 Urinalysis Laboratory Data – Shift from Baseline  – Numerical Tests: Safety 
Population  
Table 14 .3.4.6.2 Urinalysis Laboratory Data – Shift from Baselin e – Categorical Tests: Safety 
Population  
 
Other Safety Assessment s 
Table 14. 4.1 Vital Signs – Observed and Change from Baseline  by Visit: Safety Population  
Table 14.4.2  Summary of Uveitis Assessment by Visit: Safety Population  
 
Listings:  
 
Listing Numbe r Title  
Listing 16.2 .1.1 Subject Disposition and End of Participation in the Trial : Intent -to-Treat 
Population  
Listing 16.2.1.2  Inclusion and Exclusion Criteria : Intent -to-Treat Population  
Listing 16.2.2  Major Protocol Deviation s: Intent -to-Treat Popula tion 
Listing 16.2. 3 Analysis  Populations : Intent -to-Treat Population  
Listing 16.2. 4.1 Demographics and Baseline Disease Characteristics:  Intent -to-Treat 
Population  
Listing 16.2. 4.2 Crohn's Disease History : Intent -to-Treat Population  
Listing 16.2. 4.3 Medical History (excluding Crohn's disease) : Intent -to-Treat Population  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 36 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  36 Listing 16.2. 4.4 Surgical History of Crohn's disease : Intent -to-Treat Population  
Listing 16.2. 4.5 Prior Biological Agents Use : Intent -to-Treat Population  
Listing 16.2. 4.6 Prior Alcoh ol Consumption and Tobacco Use : Intent -to-Treat 
Population  
Listing 16.2.4. 7 Prior and Concomitant Medications Use: Intent -to-Treat Population  
Listing 16.2.4. 8 Prior and Concomitant Steroids  Use: Intent -to-Treat Population  
Listing 16.2.4. 9 Crohn ’s Diseas e Prior and Concomitant Medications: Intent -to-Treat 
Population  
Listing 16.2.4 .10 Concomitant Procedures : Intent -to-Treat Population  
Listing 16.2. 5.1 Drug Exposure and Compliance: Intent -to-Treat Population  
Listing 16.2. 5.2 Drug Administration: Intent -to-Treat Population  
Listing 16.2.6 .1 Crohn’s Disease Activity Index (CDAI ) Score : Intent -to-Treat 
Population  
Listing 1 6.2.6.2  Remission and  Response Parameters : Intent -to-Treat Population  
Listing 16.2.6.3  SF-36 Questionnaire Domain and Component Scores: Intent -to-Treat 
Population  
Listing 16.2.6.4  Inflammatory Bowel Disease Questionnaire (IBDQ) Score : Intent -to-
Treat Population  
Listing 16.2.6.5  Inflammation Assessment – CRP marker  
Listing 16.2.6. 6 Inflammation Assessment – Fecal calprotectin  
Listing 1 6.2.6.7  Endoscopic Assessment – CDEIS: Intent -to-Treat Population  
Listing 16.2.6.8  Endoscopic Assessment – SES-CD: Intent -to-Treat Population  
Listing  16.2.6. 9 MAP Detection: Intent -to-Treat Population  
Listing 16.2.7.1  Adverse Events : Safety  Population  
Listing 16.2. 8.1 Laboratory Assessments  -: Biochemistry: Safety  Population  
Listing 16.2. 8.2 Laboratory Assessments  – Hematology : Safety  Population  
Listing 16.2. 8.3 Laboratory Assessments  - Urinalysis : Safety  Population  
Listing 16.2. 9.1 Stool Samples  - C. Difficile Toxin : Safety  Population  
Listing 16.2. 9.2 Urine Pregnancy Test : Safety  Population  
Listing 16.2. 9.3 Uveitis Assessment : Safety  Population  
Listing 16.2.9. 4.1 12-Lead ECG  (Part 1) : Safety  Population  
Listing 16.2.9. 4.2 12-Lead ECG  (Part 2): Safety Population   
Listing 16.2.9. 4.3 12-Lead ECG  (Part 3): Safety  Population  
Listing 16.2.9. 5 Vital Signs : Safety  Population  
Listing 16.2.9. 6.1 Physical Examination  at Screening : Safety  Population  
Listing 16.2.9.6.2  Physical Examination  Significant Chang e from Previous Visit : Safety  
Population  
Excel Listing  List of Drug Exposure - combined 01 and 04  
 
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 37 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  37  
9. REFERENCES  
 
1.    International Conference of Harmonization  (ICH) E9 Expert Working Group. Statistical 
Principles for Clinical Trials: ICH Harmonized  Tripar tite Guideline. (1999) Statistics in 
Medicine; 18:1905 –1942.  
2.    SAP for the parent study RHB -104-01. 
 
10. Appendix I: Subject Data Migration from RHB -104-01 to RHB -104-04 (eCRF 
Completion Guidelines - Inform)  
 
Subject Migration  
There are two types of migratio n, Partial and Full.  Subjects who complete the 
optional screening visit receive a Partial data migration.  Subjects who did not 
complete the optional screening visit receive a full migration.  Data migrated from 
RHB -104-01 to RHB -104-04 will be frozen upo n migration.  Fields that will not be 
frozen are fields that will need to be completed during the course of the study.  
Partial Migration  (subject completes  optional screening visit)  
The only visit folders that will receive migrated data are Screening and L og Pages.  
The following is a list of folders/forms that will receive migrated data.  
Visit  Form  
Screening  Demographics  
Screening  Crohn's Disease History  
Screening  Medical History  
Screening  Surgical History for Crohn's Disease  
Log Pages  Adverse Events  
• Only adverse events that are ongoing at time of migration will be migrated 
from RHB -104-01 to RHB -104-04. 
Log Pages  Concomitant Medications  
• Only concomitant medications that are ongoing at time of migration will be 
migrated from RHB -104-01 to RHB -104-04. 
After subject/data migration is complete any forms in the Screening visit that are 
marked as not started or incomplete require data entry to be completed.  
Full Migration (subject does not complete  optional screening visit)  
The only visit folders that will receive migrated data are Screening and Log Pages.  
 STATISTICAL ANALYSIS PLAN  
RedHill Biopharma Ltd.  
RHB -104-04 
Page 38 
 
 
Version 1.0, 23 Dec 2019  
 
CONFIDENTIAL  38 The following is a list of folders/forms that will receive migrated data.  
Visit  Form  
Screening  Date of Visit  
Screening  Demographics  
Screening  Crohn's Disease History  
Screening  Medical History  
Screenin g Surgical History for Crohn's Disease  
Screening  Vital Signs Screening  
Screening  Uveitis Assessment  
Screening  12-Lead ECG  
Screening  Urine Pregnancy Test    **(Only for Female subjects)  
Screening  Urine Dipstick  
Screening  Laboratory sample collection  
Screening  MAP Testing  
Screening  MAP Culture  
Screening  Crohn's Disease Activity Index Diary  
Screening  Crohn's Disease Activity Index (CDAI)  
Screening  Inflammatory Bowel Disease Questionnaire  
Screening  Short Form -36 Health Survey  
Screening  Stool samples  
Log Pages  Adverse Events  
• Only adverse events that are ongoing at time of migration will be migrated 
from RHB -104-01 to RHB -104-04. 
Log Pages  Concomitant Medications  
• Only concomitant medications that are ongoing at time of migration will be 
migrated from  RHB -104-01 to RHB -104-04. 
After subject/data migration is complete any forms in the Screening visit that are 
marked as not started or incomplete require data entry to be completed.  
 